TDC
CDLX icon

Thompson Davis & Co’s Cardlytics CDLX Stock Holding History

Thompson Davis & Co’s Portfolio CDLX Stock Details CDLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-1,132
Closed -$12.9K – 147
2025
Q4 		$12.9K Sell
1,132
-3,405
-75% -$52.6K 0.01% 156
2025
Q3 		$111K Buy
+4,537
New +$75.6K 0.07% 131

Other funds holding CDLX

CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
KGAMU
KPS Global Asset Management (UK) London, United Kingdom $619M AUM 27.68% 1-Year Est. Return
WPM
Worldly Partners Management Needham, Massachusetts $118M AUM 19.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RC
RBF Capital San Francisco, California $2.05B AUM 29.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
QOP
Quinn Opportunity Partners Charlottesville, Virginia $1.92B AUM 31.26% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Thompson Davis & Co's CDLX Position: Q1 2026 in Review

Thompson Davis & Co sold out of Cardlytics (CDLX) in Q1 2026, closing a stake of 1,132 shares — an estimated $12.9K sold.

Thompson Davis & Co first reported a position in CDLX in Q3 2025 and held it in 2 quarters. The position peaked at $111K in Q3 2025. 58 funds tracked by Wall St. Rank hold CDLX as of Q1 2026.

  • Thompson Davis & Co reported no remaining Cardlytics position as of Q1 2026 after selling out during the quarter.
  • Thompson Davis & Co sold 1,132 Cardlytics shares in Q1 2026, an estimated $12.9K.
  • Thompson Davis & Co first reported a position in Cardlytics in Q3 2025 and held it in 2 quarters.
  • Thompson Davis & Co's Cardlytics position peaked at $111K in Q3 2025.
  • 58 funds tracked by Wall St. Rank held Cardlytics as of Q1 2026.

Based on Thompson Davis & Co's 13F filing for Q1 2026, filed 16 Apr 2026.